Daiichi exploring legal options against Ranbaxy's former promo...Ranbaxy Laboratories' majority shareholder Daiichi Sankyo said it was exploring legal options against the former promoters of Ranbaxy. Legal options could include seeking monetary damages or even initiating a lawsuit against them. Daiichi said the earlier ... Myiris, 17 hours ago |
7 images for daiichi sankyo company | ||||
Cannot comment on charges against Ranbaxy: ThakurDinesh Thakur, the Ranbaxy whistleblower, says he have no basis to comment on Daiichi Sankyo's decision to sue the Singh family for concealment and misrepresentation of data, as he left the company in 2005. Money Control, 7 hours ago
Daiichi Sankyo, Ranbaxy to integrate business in Brazil
Myiris, 1 month ago
Dinesh Thakur: Meet the man who won Rs 244 crore for blowing the whistle against Ranbaxy [India Business] [Times of India]
Pharmacy Choice, 1 week ago
|
Ranbaxy shareholders concealed critical info: Daiichi SankyoDaiichi Sankyo, the Japanese parent of Ranbaxy Laboratories, today said it believes that certain shareholders of the Indian company concealed and misrepresented critical information. The company is now pursuing legal remedies. “Daiichi Sankyo believes ... Business Standard, 1 day ago
Daiichi pursuing legal action on ex-shareholders
Smart Investor, 21 hours ago
FDA-struck Daiichi may drag Singh brothers to court
Economic Times, 1 day ago
Ranbaxy's growth in trouble with quality issues in global markets; new launches to play critical role
PharmaBiz, 1 week ago
|
Ranbaxy shares dive over 9% on bourses after Daiichi Sankyo says misled over probesFollowing the news, shares of the company opened the day on a weak note and further tanked 9.3 per cent to Rs 391 on the BSE. At NSE, the stock tumbled 9.37 per cent to Rs 390.65. Following the weakness in the stock, the market value of the company slipped by ... Economic Times, 17 hours ago
|
Daiichi may sue Ranbaxy ex-owners for hiding infoSmarting from its $500 million fine from the US Food and Drug Administration (FDA) last week, Japan's Daiichi Sankyo, the current promoter of Ranbaxy Laboratories, indicated on Wednesday that it might take legal recourse against the Indian generic ... Financial Chronicle, 1 day ago
Daiichi Sankyo Partnering 2005-2013 - new company profile report
TransWorldNews, 2 days ago
DAIICHI SANKYO COMPANY, LIMITED: Ranbaxy Announces Improved Business Standards and Quality Assurance Initiatives
4 Traders, 1 day ago
Daiichi Sankyo Announces New Executive Candidate
Noodls, 1 week ago
|
ArQule regains rights to AKT inhibitor from Daiichi SankyoArQule, Inc., a clinical-stage biotechnology company, has regained worldwide rights for the development and commercialization of compounds covered under its AKT collaboration with Daiichi Sankyo Co., Ltd., including the lead compound emerging from ... Scottrade, 1 month ago
ARQULE INC - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Pharmacy Choice, 2 weeks ago
Seattle Genetics Reports First Quarter 2013 Financial Results
Individual.com, 1 week ago
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013
EON, 1 month ago
More from: BioSpace, PR Newswire...and 35 other sources
|
Daiichi Sankyo - SWOT Framework Analysis - new company profile reportSWOT Analysis, is a strategic planning tool used to evaluate the Strengths, Weaknesses, Opportunities, and Threats involved in a project or in a business venture. It involves specifying the objective of the business venture or project and ... TransWorldNews, 1 month ago
|
Astellas, Daiichi Sankyo See New Drugs Propelling Growth--Astellas logged 5.9% growth in net profit for fiscal year ended March, but result falls short of company's, analysts' forecasts --Daiichi Sankyo returns to profit in fiscal fourth quarter, posts six-fold jump in annual net profit --Both firms ... EuroInvestor, 1 week ago
Astellas forecasts big sales growth as prostate drug catches hold
FiercePharma, 1 week ago
More from: , 4 Traders...and 1 other sources
|
Daiichi Sankyo receives approval for osteoporosis treatmentDaiichi Sankyo Company, Limited has received approval from Japan's Ministry of Health, Labour and Welfare to manufacture and market the osteoporosis treatment PRALIA subcutaneous injection 60mg syringe for the treatment of osteoporosis. PRALIA is a ... Scottrade, 1 month ago
|
Ranbaxy slumps as Daiichi says misled over probesDaiichi Sankyo made the announcement on Wednesday, 22 May 2013. Meanwhile, the BSE Sensex was down 345.63 points, or 1.72%, to 19,716.61. On BSE, 3.47 shares were traded in the counter as against an average daily volume of 1.34 lakh shares in the past one ... Business Standard, 18 hours ago
Ranbaxy tanks after Daiichi blames former shareholders for $500 mn fine
NDTV, 19 hours ago
Ranbaxy shares slump after Daiichi Sankyo says misled over probes
Sharenet, 20 hours ago
Daiichi Sankyo's net jumps to ¥66.6 bn in FY'13, annual dividend at ¥60 per share
PharmaBiz, 1 week ago
More from: Reuters, Reuters UK...and 57 other sources
|